Group 1 - MINT Income Fund has filed a notice with the Toronto Stock Exchange and received approval for a normal course issuer bid (NCIB) which will commence on May 27, 2025, and terminate on May 26, 2026 [1] - The Fund had 10,052,580 units issued and outstanding as of May 13, 2025, with 10,031,982 units in the public float [2] - The Fund may purchase up to 1,003,198 units during the 12-month period, representing 10% of the public float, and no more than 201,051 units in any 30-day period, which is 2% of the units issued and outstanding [2] Group 2 - As of May 13, 2025, the Fund had purchased 18,700 units at an average price of $6.96 per unit under its previous NCIB [2] - The Fund had the ability to purchase up to 1,089,755 units under its last NCIB, indicating a strategic approach to managing its unit purchases [2] - The manager of the Fund believes that these purchases are in the best interest of the Fund and represent a desirable use of available funds [2]

Core Insights - Clip Money Inc. reported a significant revenue growth of 225% year-over-year for Q1 2025, reaching $972,706 compared to $299,176 in Q1 2024, while costs of revenue increased by only 35% during the same period, indicating strong operating leverage [1][5]. Financial Performance - Q1 2025 revenue was $972,706, a 225% increase from Q1 2024, but down 16% quarter-over-quarter due to seasonal factors [5]. - Costs of revenue for Q1 2025 were $1,009,557, up 35% year-over-year, reflecting a much lower increase compared to revenue growth [5]. - Operating expenses rose by 9% year-over-year to $1,832,196, and net loss improved by 5% year-over-year to $2,280,281 [5]. Customer and Network Expansion - The company added 29 new shopping center locations, bringing the total to 473 ClipDrop deposit units [5]. - A partnership with Green Dot will expand the network by adding over 4,000 over-the-counter deposit locations, enhancing the scale and convenience of the Clip Network [4][5]. Product Development - Revenue from new products, including Change Orders and implementation fees, accounted for 22% of total revenue in Q1 2025, up from 9% in Q1 2024 [5]. - The company experienced a 153% increase in new deposit users and a 10% increase in average monthly deposit revenue per user [5]. Strategic Initiatives - The company is focused on expanding its U.S. business deposit network, aiming to build the largest and most convenient business deposit network in the U.S. [5]. - The board approved the grant of 965,000 restricted share units and 27,500 options to recognize performance in 2024, with vesting schedules outlined [6][7].

Core Viewpoint - Martinrea International Inc. has announced its intention to initiate a normal course issuer bid (NCIB) to repurchase up to 7,110,571 common shares over a 12-month period, representing approximately 10% of its public float [1][2]. Group 1: NCIB Details - The NCIB is set to commence on or about May 27, 2025, and will terminate on May 26, 2026, or earlier if purchases are completed [2]. - Shares will be purchased at market price through the TSX and/or alternative Canadian trading systems, with a maximum daily purchase limit of 42,323 shares based on an average daily trading volume of 169,292 shares over the last six months [2]. - As of May 21, 2025, the total number of issued and outstanding common shares is 72,787,848 [2]. Group 2: Previous Share Repurchase - In the previous 12 months, Martinrea was authorized to repurchase up to 6,435,000 shares under a prior NCIB, which ran from May 2, 2024, to May 1, 2025 [3]. - The company successfully purchased 3,977,392 shares for cancellation at a weighted average price of approximately $11.25 during the prior NCIB [3]. Group 3: Company Rationale - The company believes that its shares may trade at a price that does not reflect their true value in relation to its activities and future prospects, making the repurchase an appropriate use of corporate funds for the benefit of remaining shareholders [4]. Group 4: Company Overview - Martinrea International Inc. is a diversified global automotive supplier involved in the design, development, and manufacturing of lightweight structures and propulsion systems, operating in 56 locations across various countries [5].

Core Viewpoint - Autolus Therapeutics plc has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for the approval of its therapy, obecabtagene autoleucel (obe-cel), for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia [1][6]. Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases [9]. - The company has a pipeline of product candidates and has received FDA approval and MHRA authorization for obe-cel [9]. Product Details - Obe-cel is an autologous CD19 CAR T cell therapy designed to target B-cell precursor acute lymphoblastic leukemia [4]. - The therapy has shown a Complete Response/Complete Response with Incomplete Hematological Recovery (CR/CRi) rate of 76.6% in the pivotal cohort of the FELIX study [2]. - The median response duration for patients treated with obe-cel was 21.2 months, with median event-free survival (EFS) of 11.9 months [2]. Clinical Study Insights - The CHMP recommendation was based on the results of the FELIX study, which was an open-label, multi-center, single-arm study involving adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia [2][10]. - The study enrolled over 100 patients across 30 leading academic and non-academic centers in the U.S., U.K., and Europe [10]. Safety Profile - The most common non-laboratory Grade 3 or higher adverse reactions included unspecified infections (32%), febrile neutropenia (24%), and bacterial infectious disorders (11%) [3]. - Cytokine release syndrome occurred in 68.5% of patients, with severe cases in 2.4% [3]. Market Context - Acute lymphoblastic leukemia (ALL) is an aggressive blood cancer with approximately 6,000 new cases diagnosed annually in Europe [5]. - Conventional treatments for adult B-ALL have a median overall survival of only eight months, highlighting the need for effective therapies like obe-cel [5]. Regulatory Status - The positive CHMP opinion serves as a scientific recommendation for marketing authorization, with the European Commission expected to make a final decision within approximately two months [6][8]. - Obe-cel has already received FDA approval in November 2024 and MHRA conditional marketing authorization in April 2025 [4][6].

The Company is pleased to announce that our Chairman Edi Truell has received formal confirmation from the Swiss authorities that he is eligible, through our subsidiary GIG Services SA, “Swiss ASC”, to acquire interests in Swiss hydro power assets. Please see the full announcement attached Attachment Approval for ‘SwissASC’ to Take Stake in Swiss hydro ...

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of care chemotherapy plus PARP inhibitors achieved nearly 12-month increase in PFS compared to standard of care; median OS in IMNN-001 treatment arm not yet reached after more than five years Phase 2 OVATION 2 Study results also published in peer-reviewed journal Gynecologic Oncology LAWRENCEVIL ...

Group 1 - The presentation of Frontline plc's first quarter 2025 results is scheduled for a webcast/conference call on May 23, 2025, at 15:00 CET [1] - The information is subject to the disclosure requirements under the Norwegian Securities Trading Act [1]

Juve Stabia’s continued advance in the Serie A playoffs will once again be streamed live and air free in the United States, Canada and United Kingdom, building both Brera Holdings’ and the Club’s profiles S.S. Juve Stabia’s second semifinal match in the Serie A playoffs at Cremonese will be available live and air free in the United States, Canada and the United Kingdom via Destination Calcio TV S.S. Juve Stabia’s second semifinal match in the Serie A playoffs at Cremonese will be available live and air fr ...

SINGAPORE, May 23, 2025 (GLOBE NEWSWIRE) -- GCL Global Holdings Ltd. (NASDAQ: GCL) (“GCL” or the “Company”), a leading provider of games and entertainment, today announced that the Company will be participating in an upcoming investor conference. Maxim Group’s 2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow Fireside Chat Who: Sebastian Toke, Group CEOWhen: Track 1 from 9:00-9:30a.m. EDT on June 4, 2025Where: Virtual Contact Maxim Group salesperson for access. About GCL Global Holdi ...

SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY. Jefferies Global Healthcare Conference 2025Company presentation: Thursday, June 5, 2025 at 12:50 p.m. Eastern TimeWebcast link: HERE The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at ...